Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT
Health Technology Assessment2021Vol. 25(68), pp. 1–114
Citations Over TimeTop 18% of 2021 papers
Adam Devall, Justin Chu, Leanne Beeson, Pollyanna Hardy, Versha Cheed, Yongzhong Sun, Tracy Roberts, Chidubem B. Ogwulu, Eleanor Williams, Laura Jones, Jenny La Fontaine, Ruth Bender-Atik, Jane Brewin, Kim Hinshaw, Meenakshi Choudhary, Amna Ahmed, J. Naftalin, Natalie Nunes, Abigail Oliver, Feras Izzat, Kalsang Bhatia, Ismail Hassan, Yadava Jeve, J. Hamilton, Shilpa Deb, Cecilia Bottomley, Jackie Ross, Linda Watkins, Martyn Underwood, Ying Cheong, Chitra Kumar, Pratima Gupta, Rachel Small, Stewart Pringle, Frances Hodge, Anupama Shahid, Ioannis Gallos, Andrew W. Horne, Siobhan Quenby, Arri Coomarasamy
Abstract
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 68. See the NIHR Journals Library website for further project information.
Related Papers
- → Septic shock after medical abortions with mifepristone (Mifeprex, RU 486) and misoprostol(2005)14 cited
- → Medical abortion with mifepristone and misoprostol at 13–22 weeks: how long between the mifepristone and the misoprostol?(2015)2 cited
- Cause analysis of failure of medical abortion with mifepristone and misoprostol application of 24 cases of uterine scar(2009)
- Clinical Analysis of Mifepristone Combined with Misoprostol on Therapy of Missed Abortion(2011)
- EFFECT OF MIFEPRISTONE AND MISOPROSTOL ON MISSED ABORTION(2003)